`
`In responseto the Restriction Requirement, Applicant elects with traverse, Group | (claims 1-
`
`30 and 34-35) drawn to a modified PH20 polypeptide.
`
`With regard to the traversal, the Examiner has required restriction between claims drawn to a
`
`product and claims drawn to a process of making and/or using the product. Where Applicant elects
`
`claims directed to the product, and all the product claims are subsequently found allowable,
`
`withdrawnprocessclaims that includeall the limitations of the allowable product claims should be
`
`considered for rejoinder. See MPEP § 821.04(b). Here, the features of the modified PH20
`
`polypeptide as set forth in claim 1 are all included in the methodfor treating a hyaluronan-
`
`associated disease or condition as set forth in claims 31-33. For this reason alone, rejoinder of claims
`
`31-33 is proper and requested by Applicantin view of the above remarks.
`
`Applicant is thus entitled to a rejoinder of the non-elected claims should the elected claims be
`
`deemed allowable.
`
`Conclusion
`
`In view of the foregoing, Applicant awaits a favorable action on the merits. Should the
`
`Examiner feel that there are any issues outstanding after consideration of this response, the
`
`Examiner is invited to contact the undersigned representative to expedite prosecution.
`
`Date: March 5, 2024
`
`MORGANLEWIS & BOCKIUS LLP
`1111 Pennsylvania Ave, NW
`Washington, DC 20004
`Customer Number: 28977
`Telephone: 202.739.5139
`robert.smyth@morganlewis.com
`
`Respectfully submitted,
`
`By: /Kalpesh V. Upadhye/
`Kalpesh V. Upadhye,Ph.D.
`Registration No. 70,236
`
`Robert Smyth, Ph.D.
`Registration No. 50,801
`
`DB1i/ 144937442.1
`
`5
`
`